Research Grant
[Cite as https://purl.org/au-research/grants/arc/DP0208117]Researchers: Sue Berners-Price (Chief Investigator) , Nicholas Farrell (Partner Investigator)
Brief description DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.
Funding Amount $290,000
Funding Scheme Discovery Projects
- PURL : https://purl.org/au-research/grants/arc/DP0208117
- ARC : DP0208117